Results 271 to 280 of about 220,141 (335)

Risk Factors for Infectious Adverse Events in Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Venetoclax Combinations: A Retrospective Single-Centre Real-World Experience. [PDF]

Cancer Rep (Hoboken)
Çınar OE, Kanat A, Erer K, Şahin R, Eren EE, Yıldızhan E.   +5 more
europepmc   +1 more source

Long‐term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236‐week, Phase 3 trial results

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this Phase III study, secukinumab demonstrated sustained efficacy and a favourable safety profile in paediatric patients with chronic severe plaque psoriasis over a treatment period of 236 weeks. Abstract Background Plaque psoriasis, a chronic inflammatory disease, affects up to 2.1% of the global paediatric population.
Andrzej Kaszuba, Philemon Papanastasiou, Dorota Krasowska, Raul De Lucas Laguna, Michael Ziv, Shoba Ravichandran, Amita Bansal, Swapnil S. Dahale, Ruvie Martin, Bertrand Paguet, Nina Magnolo, Kulli Kingo   +11 more
wiley   +1 more source

Cytopenias in context: ethnoracial hematological trends among HIV-infected Africans and Russians: a review. [PDF]

Ann Med Surg (Lond)
Obeagu EI, Goryavheva OG, Zubarev MA.
europepmc   +1 more source

Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68‐week randomized Phase 3 trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This open‐label study is a continuation of the 16‐week double‐blind, Phase 3 trial assessing the efficacy and safety of brodalumab 210 mg subcutaneously, till a 68‐week extension period. Continued improvement was seen in the PPPASI 50/75/90 responses, PPPSI scores, PGA 0/1 responses and DLQI. Abstract Background The efficacy and safety of brodalumab in
Masamoto Murakami, Yukari Okubo, Satomi Kobayashi, Natsuko Kikuta, Yoshiumi Ouchi, Kenta Shishido, Tadashi Terui   +6 more
wiley   +1 more source

Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The current study found no evidence of cumulative increased safety risks with upadacitinib 15 or 30 mg for up to 6 years and over 9000 patient‐years of safety data in adults and adolescents. There were low rates of adjudicated major adverse cardiovascular events, adjudicated thromboembolic events and malignancies. Abstract Background Atopic dermatitis (
Christopher G. Bunick, Alan D. Irvine, Jonathan I. Silverberg, Emma Guttman‐Yassky, Mona Shahriari, Xinghua Gao, Stephan Weidinger, Norito Katoh, Namita Vigna, Deanne M. Dilley, Elvira D'Andrea, Henrique D. Teixeira, Andrew M. Platt, Gweneth F. Levy   +13 more
wiley   +1 more source

Impacts of polymorphisms in drug-metabolizing enzyme and transporter genes on irinotecan toxicity and efficacy in Thai colorectal cancer patients. [PDF]

PLoS One
Akarapredee N, Atasilp C, Sukasem C, Jinda P, Sukprasong R, Jensuriyarkun J, Wongjitjanyong S, Satapornpong P, Vanwong N.   +8 more
europepmc   +1 more source

Inflammatory and Immunological Basis of Periodontal Diseases

Journal of Periodontal Research, EarlyView.
The periodontal lesion emerges as an evolving immunological battlefield, where host–microbiome interactions, dysregulated immune responses, fragile resolution mechanisms, and inflammophilic dysbiosis converge to shift the balance from homeostasis to unrestrained tissue destruction.
Giacomo Baima, Marion Arce, Mario Romandini, Thomas Van Dyke   +3 more
wiley   +1 more source

Isolated Chronic Neutropenia in Adults: Causes, Diagnostic Work-Up, and Management-A Narrative Review. [PDF]

J Clin Med
Njue L, Porret N, Andres M, Rovó A.
europepmc   +1 more source

Salivary and Serum Cytokine Concentrations in Kidney Transplantation: A Prospective Study

Oral Diseases, EarlyView.
ABSTRACT Background Kidney transplant recipients (KTRs) experience immune modulation, which may lead to graft rejection and other adverse outcomes. Although serum cytokines are well‐established systemic immune markers, the role of salivary biomarkers has never been reported in the literature.
Luciano Miziara, Marcio Augusto de Oliveira, Debora Macedo, Ligia Pierrotti, Fabiana Agena, Elias David‐Neto, Aluísio Cotrim Segurado, Rodrigo Zerbinati, Marina Gallottini, Paulo Braz‐Silva, Fabiana Martins   +10 more
wiley   +1 more source

Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapy. [PDF]

Hemasphere
Scheller L, Zhou X, Loeffler-Wirth H, Kreuz M, Kadel SK, Schimanski S, Schulze H, Ruckdeschel A, Eisele F, Konetzki V, Jornet Culubret M, Merz M, Mersi J, Waldschmidt J, Danhof S, Köhl U, Kortüm KM, Rasche L, Einsele H, Düll J, Topp MS, Hudecek M, Reiche K, Alb M.   +23 more
europepmc   +1 more source